TransMolecular, Inc. Presents New Information on Distinct Anti-Angiogenic Mechanism-of-Action of TM601

CAMBRIDGE, Mass.--(BUSINESS WIRE)--TransMolecular, Inc. today presented preclinical data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting demonstrating new information on the anti-angiogenic mechanism-of-action of TM601. According to the abstract, TM601 binding co-localizes with annexin A2 on the surface of activated vascular endothelial cells in choroidal neovascularization (CNV) lesions, induces apoptosis and causes CNV regression. The data were highlighted in ARVO poster number 1164/D1126. TM601 is a novel, wholly synthetic peptide, found to have robust anti-angiogenic activity in neovascular diseases, including ophthalmic disease and cancer.